Literature DB >> 1985693

Erythropoietin mRNA levels are governed by both the rate of gene transcription and posttranscriptional events.

M A Goldberg1, C C Gaut, H F Bunn.   

Abstract

The human hepatoma cell line, Hep3B, synthesizes large quantities of erythropoietin (Epo) mRNA and protein in a regulated manner in response to hypoxia and cobaltous chloride (CoCl2). To further understand the regulation of Epo gene expression, we studied the effects of hypoxia and CoCl2 on the rate of Epo gene transcription. While Northern blot analyses showed that steady-state Epo mRNA levels increase more than 50-fold in response to hypoxia or CoCl2, nuclear run-off experiments demonstrated only a 10-fold increase in Epo gene transcription in response to these stimuli. In the presence of either actinomycin D (Act D) or cycloheximide, the stability of biologically functional Epo mRNA was much greater than that observed in the absence of these agents and much greater than that which has been reported in vivo. These findings suggest that the stability of Epo mRNA is modulated by the transcription and translation of rapidly turning over gene product(s). Thus, Epo mRNA levels are determined by both the rate of gene transcription and posttranscriptional events. These experiments demonstrate a potential pitfall in estimating mRNA half-lives based on Act D chase experiments alone.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1985693

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  32 in total

1.  A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation.

Authors:  G L Semenza; G L Wang
Journal:  Mol Cell Biol       Date:  1992-12       Impact factor: 4.272

Review 2.  Adaptive and maladaptive cardiorespiratory responses to continuous and intermittent hypoxia mediated by hypoxia-inducible factors 1 and 2.

Authors:  Nanduri R Prabhakar; Gregg L Semenza
Journal:  Physiol Rev       Date:  2012-07       Impact factor: 37.312

3.  Human erythropoietin gene delivery using an arginine-grafted bioreducible polymer system.

Authors:  Youngsook Lee; Hye Yeong Nam; Jaesung Kim; Minhyung Lee; James W Yockman; Sug Kyun Shin; Sung Wan Kim
Journal:  Mol Ther       Date:  2012-04-03       Impact factor: 11.454

Review 4.  mRNA stability in mammalian cells.

Authors:  J Ross
Journal:  Microbiol Rev       Date:  1995-09

5.  Hypoxia-inducible nuclear factors bind to an enhancer element located 3' to the human erythropoietin gene.

Authors:  G L Semenza; M K Nejfelt; S M Chi; S E Antonarakis
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-01       Impact factor: 11.205

6.  Enhanced expression of glucose-6-phosphate dehydrogenase in human cells sustaining oxidative stress.

Authors:  M V Ursini; A Parrella; G Rosa; S Salzano; G Martini
Journal:  Biochem J       Date:  1997-05-01       Impact factor: 3.857

7.  Hypoxic regulation of vascular endothelial growth factor mRNA stability requires the cooperation of multiple RNA elements.

Authors:  J A Dibbens; D L Miller; A Damert; W Risau; M A Vadas; G J Goodall
Journal:  Mol Biol Cell       Date:  1999-04       Impact factor: 4.138

8.  Interaction of nitric oxide and cyclic guanosine 3',5'-monophosphate in erythropoietin production.

Authors:  T Ohigashi; J Brookins; J W Fisher
Journal:  J Clin Invest       Date:  1993-09       Impact factor: 14.808

9.  The orphan receptor hepatic nuclear factor 4 functions as a transcriptional activator for tissue-specific and hypoxia-specific erythropoietin gene expression and is antagonized by EAR3/COUP-TF1.

Authors:  D L Galson; T Tsuchiya; D S Tendler; L E Huang; Y Ren; T Ogura; H F Bunn
Journal:  Mol Cell Biol       Date:  1995-04       Impact factor: 4.272

10.  Distinct regulatory mechanisms of the human ferritin gene by hypoxia and hypoxia mimetic cobalt chloride at the transcriptional and post-transcriptional levels.

Authors:  Bo-Wen Huang; Masaki Miyazawa; Yoshiaki Tsuji
Journal:  Cell Signal       Date:  2014-08-27       Impact factor: 4.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.